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ABSTRACT 23 
Age at onset in spinocerebellar ataxia type 3 (SCA3/MJD) is incompletely explained by 24 
the size of the CAG tract at the ATXN3 gene, implying the existence of genetic 25 
modifiers. A role of inflammation in SCA3 has been postulated, involving altered 26 
cytokines levels; promoter variants leading to alterations in cytokines expression could 27 
influence onset. Using blood from 86 SCA3 patients and 106 controls this work aimed 28 
to analyse promoter variation of four cytokines (IL1A, IL1B, IL6 and TNF) and to 29 
investigate the association between variants detected and their transcript levels, 30 
evaluated by quantitative PCR. Moreover, the effect of APOE isoforms, known to 31 
modulate cytokines, was investigated. Correlations between cytokine variants and 32 
onset were tested; the cumulative modifier effects of cytokines and APOE were 33 
analysed. Patients carrying the IL6*C allele had a significant earlier onset (4 years in 34 
average) than patients carrying the G allele, in agreement with lower mRNA levels 35 
produced by IL6*C carriers. The presence of APOE*ɛ2 allele seems to anticipate onset 36 
in average 10 years in patients carrying the IL6*C allele; a larger number of patients 37 
will be needed to confirm this result. These results highlight the pertinence of 38 
conducting further research on the role of cytokines as SCA3 modulators, pointing to 39 
the presence of shared mechanisms involving IL6 and APOE. 40 
 41 
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INTRODUCTION 44 
Spinocerebellar ataxia type 3 (SCA3/MJD; MIM#109150; ORPHA98757) is the most 45 
common spinocerebellar ataxia worldwide. The number of coding CAG repeats at the 46 
causative locus, ATXN3, explains from 50% to 75% of the age at onset variance (revised 47 
in Bettencourt and Lima 2011) therefore implying the existence of additional familial 48 
factors, namely genetic. Several genetic modifiers have been proposed: the number of 49 
CAG repeats at several expansion loci (Jardim et al. 2003; Raposo et al. 2015; Tezenas 50 
du Montcel et al. 2014); allelic variants at the apolipoprotein E (APOE) (Bettencourt et 51 
al. 2011; Peng et al. 2014) and glucosidase, beta, acid (GBA) genes (Siebert et al. 2012); 52 
variation in the 3’UTR at the ATXN3 gene (Long et al. 2015) as well as the size of the 53 
normal SCA3 allele (França et al. 2012). In the ATXN3 gene a repeat expansion above 54 
50 triplets encodes an abnormally long polyglutamine (polyQ) stretch in the ataxin-3 55 
protein (Maciel et al. 2001); mutant ataxin-3 is prone to misfolding and aggregation, 56 
triggering a cascade of pathological events (Evers et al. 2014). The putative role of 57 
inflammation, namely the behaviour of interleukine 1 alpha (IL1A), interleukine 1 beta 58 
(IL1B), interleukine 6 (IL6) and tumor necrosis factor (TNF), has been investigated in 59 
polyQ diseases (Olejniczak et al. 2015). In SCA3 brain tissue, IL1β and IL6 staining was 60 
found to be enhanced, as compared to controls; activated microglia and reactive 61 
astrocytes have also been observed (Evert et al. 2001, 2003, 2006). Recently, eotaxin 62 
was found to be higher in serum of SCA3 asymptomatic carriers and in patients (da 63 
Silva Carvalho et al. 2015). IL1A c.-889C>T, IL1B c.-511C>T, IL6 c.-174G>C and TNF c.-64 
308G>A localized at the promoter of respective cytokine genes have been related in 65 
vitro, ex and in vivo studies with differences in mRNA and/or protein levels of these 66 
cytokines (Dominici et al. 2002; Fishman et al. 1998; Hall et al. 2004; Wilson et al. 67 
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1997). Moreover, a link between APOE and cytokines has been investigated, since 68 
APOE modulates inflammatory and immune responses in an isoform-dependent 69 
manner (Zhang et al. 2011). We have previously shown that the APOE*ɛ2 allele was 70 
significantly associated with an earlier age at onset in a cohort of SCA3 Azorean 71 
patients (Bettencourt et al. 2011). 72 
Given a possible role of inflammation in SCA3, we hypothesised that promoter variants 73 
leading to alterations of expression levels of cytokines could influence disease 74 
manifestation, namely onset. Using peripheral blood from a homogenous Azorean 75 
cohort of SCA3 patients the present work aimed to analyse variants in the promoter 76 
regions of four main cytokines: IL1A c.-889C>T (rs1800587), IL1B c.-511C>T (rs16944), 77 
IL6 c.-174G>C (rs1800795) and TNF c.-308G>A (rs1800629), and to investigate the 78 
association between these variants and the respective transcript levels. Genotype-79 
phenotype correlations were performed to test the loci previously reported as 80 
potential modifiers of SCA3 onset. Moreover, the cumulative modifier effects of 81 
cytokines loci and APOE were also tested.  82 
  83 
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SUBJECTS AND METHODS 84 
Subjects 85 
Eighty six Azorean SCA3 patients, confirmed as carriers of the ATXN3 mutation and 106 86 
apparently healthy controls, were included in this study. Controls were selected taking 87 
into account the ancestry, age and gender distribution of cases. The size of the (CAG)n 88 
tract was determined as previously reported (Bettencourt et al. 2008). Age at onset, 89 
defined as the age of appearance of gait disturbance and/or diplopia reported by the 90 
patient and/or a close relative, was recorded during clinical assessments performed at 91 
the Department of Neurology (Hospital do Divino Espírito Santo - HDES, Ponta 92 
Delgada). APOE genotypes from SCA3 patients were considered for statistical analysis; 93 
genotyping was performed as in Bettencourt and colleagues (Bettencourt et al. 2011). 94 
All samples were collected after informed consent. This study is a part of a project 95 
approved by the Ethics Committee of HDES. 96 
 97 
DNA isolation and multiplex PCR-RFLP 98 
DNA was extracted from all samples using standard procedures. A multiplex PCR– 99 
Restriction Fragment Length Polymorphism (RFLP) was developed to analyse variants 100 
in the promoter of four cytokines: IL1A c.-889C>T (rs1800587), IL1B c.-511C>T 101 
(rs16944), IL6 c.-174G>C (rs1800795) and TNF c.-308G>A (rs1800629). The set of 102 
primers (0.2μM of each one per reaction) for each cytokine variant as well as multiplex 103 
PCR-RFLP reactions mixture and conditions are described in supplementary Table 1. 104 
 105 
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RNA isolation and qPCR 106 
A subset of 54 SCA3 patients were selected to measure cytokines mRNA levels. Signs of 107 
inflammatory or infective conditions were annotated by accessing the clinical records 108 
of patients; patients presented any of the abovementioned conditions were not 109 
included. mRNA cytokine levels were also determined in 33 controls. Four pre-110 
validated TaqMan Gene Expression Assays (Hs00174092_m1, Hs01555410_m1, 111 
Hs00985639_m1 and Hs99999043_m1 from Applied Biosystems) were used to 112 
measure cytokines mRNA levels. RNA isolation and quantification, cDNA synthesis, 113 
quantitative PCR (qPCR) conditions, as well as calculation of relative expression values 114 
have been performed as described elsewhere (Raposo et al. 2015). 115 
 116 
Statistical analysis 117 
Allele and genotype frequencies were estimated for all analysed loci and Hardy-118 
Weinberg equilibrium (HWE) was tested. Allelic/genotypic frequencies for controls 119 
(N=106) were compared with available data for other European and non-European 120 
populations. An ANCOVA, using age at sampling as covariate, was run to compare 121 
transcript levels between cytokine genotypes. The effects of the CAG length in 122 
expanded allele on age at onset, as well as the presence/absence of each cytokine 123 
allelic variant were assessed using a linear fitting model. Equality of variances between 124 
groups was verified by the Levene’s test. An ANCOVA, using the CAG length in 125 
expanded allele as covariate, was conducted to compare estimated age at onset 126 
between: (1) cytokine genotypes; or (2) cytokine alleles; or (3) interaction of APOE*ɛ2 127 
allele and cytokine genotypes; or (4) interaction of APOE*ɛ2 allele and allelic variants. 128 
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For two or more pairwise comparisons (comparisons between cytokine genotypes), p-129 
values were adjusted using the Bonferroni procedure. Significant effects resulting from 130 
the ANCOVA comparisons, obtained only for IL6 allelic variants, were further tested. 131 
These correlations were confirmed: a) using a generalized estimating equation test, 132 
where kinship was used as repetitive measure within-subjects; and b) using the subset 133 
of 38 unrelated SCA3 patients (patients who shared grand-parents were considered 134 
related). All statistical analyses were performed in IBM SPSS Statistics 22 (IBM Corp. 135 
Released 2013). A statistically significant result lower than 0.05 was considered for all 136 
tests performed.   137 
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RESULTS 138 
Gender and age at collection for the studied subjects are shown in Figure 1. Genotypes 139 
for the ATXN3 locus (N=86) in patients, as well as relevant clinical data are displayed in 140 
Figure 1.  141 
Loci were in conformity with Hardy-Weinberg equilibrium expectations, with the 142 
exception of IL1A and IL6 loci in SCA3 patients (supplementary Table 2). Pairwise 143 
differentiation exact test failed to detect significant differences in allelic or genotypic 144 
IL1A, IL1B and TNF frequencies between SCA3 patients and population-matched 145 
controls. At the IL6 locus, a statistically significant difference was obtained when 146 
comparing all patients with controls, which should reflect the excess of the C allele in 147 
the patients group; no differences, however, were detected when considering only 148 
unrelated patients (supplementary Table 2). 149 
In SCA3 patients, no significant differences were obtained when comparing mRNA 150 
levels by genotypes (Figure 2). The effects of promoter allelic variants on mRNA levels 151 
were confirmed: the IL1A*T allele, the IL1B*T allele, the IL6*G allele and the TNF*A 152 
allele were associated with higher mRNA levels (Figure 2), in accordance with previous 153 
studies. The mRNA levels by cytokine genotype varied similarly in controls (data not 154 
shown).  155 
A negative correlation between the size of ATXN3 expanded allele of SCA3 patients 156 
and age at onset was observed (N=86, r=−0.804, p<0.0005). The explanation of the age 157 
at onset variance provided by the CAG length in expanded allele was 65% (F=154.1, 158 
p<0.0005). An improvement of the previously model was observed only when the 159 
presence/absence of the IL6*C variant was added, which significantly contributed to 160 
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the variance of the age at onset, by additionally explaining 1.9% (N=86, Part 161 
correlation coefficient=0.138, p<0.05).  162 
Patients carrying the IL1A*T allele or the IL1B*T allele or the IL6*C allele all showed a 163 
tendency for an earlier age at onset (adjusted for mean CAG length) compared to 164 
patients homozygous for IL1A*C allele or the IL1B*C allele or the IL6*G allele 165 
(supplementary Table 3). Age at onset was anticipated by 4 years in average in patients 166 
carrying the IL6*C (N=66) (F(1,83)=4.7, p=0.03). The use of a generalized estimating 167 
equation test accounting for relatedness, and the earlier onset in patients carrying the 168 
IL6*C allele confirmed that this result was not due to patients relatedness (Wald Χ2 = 169 
3.8; p=0.05); the same tendency was observed when analysing only unrelated patients 170 
(N=38). In the present cohort (N=86), the presence of the APOE*ɛ2 allele explained 171 
3.4% (p=0.003) of variance in age at onset. The presence of APOE*ɛ2 allele significantly 172 
anticipated onset in average 10 years in patients carrying one or two copies of the 173 
IL6*C allele (p=0.005, Figure 3). Fitting a linear model, estimated age at onset 174 
(F(3,81)=63.001, p<0.0005) using the APOE and IL6 loci alongside with the CAG size in 175 
expanded allele could be calculated applying the formula: age at onset = 230.117 – 176 
2.686 x (CAGn in expanded allele) – 3.272 x (presence/absence of IL6*C allele) – 6.911 x 177 
(presence/absence of APOE*ɛ2 allele). 178 
  179 
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DISCUSSION 180 
 A significant association between IL6 c.-174G>C variation and age at onset was, 181 
nevertheless, identified; patients carrying the IL6*C allele presented, in average, an 182 
onset four years earlier than the one displayed by patients homozygous for the G 183 
allele. We further observed a tendency for lower mRNA levels in patients carrying the 184 
IL6*C allele compared to GG homozygous, a result which is in agreement with previous 185 
findings (Fishman et al. 1998). Fishman and colleagues had suggested that IL6 c.-186 
174G>C variation is near to a glucocorticoid receptor (GR) binding site as well as G>C 187 
position could potentiate the creation for a binding site for the transcription factor 188 
nuclear factor 1 (NF1), implying, in both cases, the repression of transcription (Fishman 189 
et al. 1998). In our cohort, the low mRNA levels of IL6 produced by the IL6*C carriers 190 
were associated with a premature SCA3 onset, suggesting that in SCA3 patients’ cells, 191 
such low levels could negatively contribute to cellular dysfunction, leading to the 192 
premature appearance of the first symptoms. Nishimura and colleagues (Nishimura et 193 
al. 2001) previously reported an association between IL1B*C allele and SCA6 onset; 194 
however, this association was not confirmed in our cohort of patients. In this study, an 195 
anticipation of onset (average of 10 years) was observed in patients carrying the 196 
APOE*ɛ2 allele and one or two copies of the IL6*C allele. Although there is no 197 
published data for IL6, APOE is known to suppress the secretion of TNF and IL1B, the 198 
APOE*ɛ2 isoform being associated with the lowest levels of secretion (Zhang et al. 199 
2011).  200 
Even considering the homogeneity features of our patient’s cohort, since sample size 201 
in this study is limited, the genotype-phenotype associations described should be 202 
replicated in a larger Azorean sample, when available, as well as in independent 203 
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cohorts. Globally, results highlight the pertinence of further research on the role of 204 
cytokines as modulators of SCA3 onset, pointing to the presence of shared 205 
mechanisms involving IL6 and APOE.  206 
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FIGURE LEGENDS 311 
Figure 1. Demographic data and clinical features for studied individuals. 312 
Figure 2. Cytokines mRNA levels (shown as 2-ΔCt) by genotypes in 54 SCA3 patients. 313 
Expression values were adjusted for age at blood collection (50 years). ). In the 314 
comparisons performed by IL1A or IL6 genotype, Bonferroni adjusted p-values were 315 
obtained by an ANCOVA procedure. IL1B and TNF mRNA levels were not successfully 316 
quantified for one patient. 317 
Figure 3. Estimated age at onset was calculated taking in consideration the cumulative 318 
effect of APOE*e2 allele and IL6 variation. ≠1The difference was in average of 4 years 319 
(ANCOVA, p=0.03). ≠2The difference was in average of 10 years (t-test, p=0.005). T-test 320 
was calculated using the OpenEpi, version 3.03 (Dean AG, Sullivan KM, Soe MM. OpenEpi: 321 
Open Source Epidemiologic Statistics for Public Health. www.OpenEpi.com, updated in 322 
2014/09/22). APOE genotype was not successfully obtained in one patient. 323 
  324 
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SUPPLEMENTARY MATERIAL 325 
Supplementary Table 1. Multiplex PCR primers, size of amplified fragments, restriction 326 
enzymes, size of restriction fragments as well as PCR-RFLP reactions mixture and 327 
conditions.  328 
Supplementary Table 2. Genotypic, allelic frequencies and p-values for the Hardy-329 
Weinberg equilibrium test for each cytokine loci studied in all and unrelated SCA3 330 
patients and population-matched controls. Differentiation exact test p-values are also 331 
shown. 332 
Supplementary Table 3. Genetic and clinical features of the 86 SCA3 patients divided 333 
by cytokines alleles, as well as presence/absence of APOE*ɛ2 allele. 334 
Figure 1 
 
Figure 2 
 
Figure 3 
 
Supplementary Table 1. Multiplex PCR primers, size of amplified fragments, restriction 
enzymes, size of restriction fragments as well as PCR-RFLP reactions mixture and 
conditions. 
 PCR RFLP  
 Primers sequence 5’ – 3’ Product size (bp)  
IL1α c.-889C>T 
IL1α-F1 TGTTCTACCACCTGAACTAGGC 
99 
NcoI   
IL1α-R1 TTACATATGAGCCTTCCATG  C → 79 + 20 T → 99  
IL1β c.-511C>T 
IL1β-F2 TGGCATTGATCTGGTTCATCCA 
244 
AvaI   
IL1β-R CCTGTCTGTATTGAGGGTG  C → 190 + 54 T → 244  
IL6 c.-174G>C 
IL6-F CAGAAGAACTCAGATGACTGGT 
377 
NcoI   
IL6-R TGCAATGTGACGTCCTTTAC  G → 351 + 26 C → 377  
TNFα c.-308G>A 
TNFα-F3 GAGGCAATAGGTTTTGAGGGCCAT 
147 
NcoI   
TNFα-R3 GGGACACACAAGCATCAAG  G →126 + 21 A → 147  
Reaction mixture 
 0.4mM each dNTP 
1x NH4 Buffer 
3mM MgCl2 solution 
1x HiSpec solution 
2U BIOTAQ DNA polymerase 
(Bioline) 
200ng genomic DNA 
 
1X reaction buffer Tango (10X) 
5U NcoI 
5U AvaI (Thermo Fisher 
Scientific) 
3μl PCR product 
  
 Total volume 25μl    10μl 
Thermocycler/Thermoblock conditions 
 initial denaturation: 95°C, 5min 
34 cycles  
denaturation: 95°C, 30s 
annealing: 58°C, 90s 
extension: 72°C, 45s 
final extension: 72°C , 10min 
 
Incubation: overnight, 37°C 
(the digested product run on a 
14% PAGE gel and was 
revealed using a silver nitrate 
standard protocol) 
  
_ mismatch primers (point mutation) 
1Primers pair: De Freitas NM, Imbronito A V., Neves AC, Nunes FD, Pustiglioni FE, Lotufo RFM. Analysis 
of IL-1A(-889) and TNFA(-308) gene polymorphism in Brazilian patients with generalized aggressive 
periodontitis. Eur Cytokine Netw. 2007;18(3):142–7; 2Primer forward: Brett PM, Zygogianni P, Griffiths 
GS, Tomaz M, Parkar M, D’Aiuto F, et al. Functional Gene Polymorphisms in Aggressive and Chronic 
Periodontitis. J Dent Res. 2005 1;84(12):1149–53; 3Primers pair: Moorchung N, Srivastava AN, Gupta 
NK, Ghoshal UC, Achyut BR, Mittal B. Cytokine gene polymorphisms and the pathology of chronic 
gastritis. Singapore Med J. 2007;48(5):447–54.  
 
Supplementary Table 2. Genotypic, allelic frequencies and p-values for the Hardy-Weinberg 
equilibrium test for each cytokine loci studied in all and unrelated SCA3 patients and 
population-matched controls. Differentiation exact test p-values are also shown. 
   SCA3 patients 
Controls (C), 
N=106 
Differentiation test p-value# 
   
All,  
N=86 
Unrelated (U), 
N=38 
C. versus all C. versus U. 
IL1α c.-889C>T 
(rs1800587) 
Fr
eq
u
en
ci
es
 
G
en
o
ty
p
e
 CC 0.424 0.474 0.491 
0.139 0.200 CT 0.365 0.263 0.396 
TT 0.212 0.263 0.113 
al
le
le
 C 0.606 0.605 0.689 
0.099 0.153 
T 0.394 0.395 0.311 
   Hardy-Weinberg equilibrium   
   0.038 0.006 0.495   
        
IL1β c.-511C>T 
(rs16944) 
Fr
eq
u
en
ci
es
 
G
en
o
ty
p
e
 CC 0.558 0.500 0.462 
0.136 0.523 CT 0.419 0.474 0.481 
TT 0.023 0.026 0.061 
al
le
le
 C 0.767 0.737 0.703 
0.181 0.555 
T 0.233 0.263 0.297 
   Hardy-Weinberg equilibrium   
   0.141 0.403 0.163   
        
IL6 c.-174G>C 
(rs1800795) 
Fr
eq
u
en
ci
es
 
G
en
o
ty
p
e
 GG 0.232 0.395 0.452 
0.002 0.253 GC 0.628 0.447 0.462 
CC 0.140 0.158 0.086 
al
le
le
 G 0.546 0.618 0.684 
0.006 0.261 
C 0.454 0.382 0.316 
   Hardy-Weinberg equilibrium   
   0.019 0.739 0.316   
        
TNFα c.-308G>A 
(rs1800629) 
Fr
eq
u
en
ci
es
 
G
en
o
ty
p
e
 GG 0.640 0.579 0.755 
0.121 0.122 GA 0.337 0.421 0.226 
AA 0.023 0 0.019 
al
le
le
 G 0.808 0.790 0.868 
0.126 0.141 
A 0.192 0.210 0.132 
   Hardy-Weinberg equilibrium   
   0.726 0.171 1.000   
        
#p-value was calculated by exact G test in Genepop software (Raymond M. & Rousset F, 1995. GENEPOP 
(version 1.2): population genetics software for exact tests and ecumenicism. J. Heredity, 86:248-249 
Rousset, F., 2008. Genepop'007: a complete reimplementation of the Genepop software for Windows and 
Linux. Mol. Ecol. Resources 8: 103-106). 
Pairwise differentiation exact test (Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated 
software package for population genetics data analysis. Evol Bioinform Online. 2005;1:47–50) for genotypic 
frequencies between apparently healthy Azorean individuals versus individuals from: 
(1) mainland Portugal – no differences significant for IL1β, IL6 and TNFα loci, no data available for IL1α locus 
(REFs); 
(2) Europe – differences significant for IL6 and TNFα loci, not significant for IL1α and IL1β loci; 
(3) Asia – differences significant for IL1α, IL1β and TNFα loci, no data available for IL6 locus; 
(4) Africa – differences significant for IL1α and IL1β loci, not significant for TNFα locus, no data available for 
IL6 locus. 
Genotypes from European, Asiatic and African samples were obtained in dbSNP, NCBI 
(http://www.ncbi.nlm.nih.gov/snp/). 
 
Supplementary Table 3. Genetic and clinical features of the 86 SCA3 patients divided by 
cytokines alleles, as well as presence/absence of APOE*ɛ2 allele. 
   CAG length   
 
Alleles N 
Normal 
allele 
Expanded 
allele 
Age at 
onset* 
Disease 
duration 
IL1A c.-889C>T 
C 37 22±4 71±3 39±1 12±8 
T 48 21±5 70±4 37±1 11±9 
 
IL1B c.-511C>T 
C 49 22±5 71±4 38±1 11±8 
T 37 22±5 70±4 38±1 11±9 
 
IL6 c.-174G>C 
G 20 20±5 70±4 41±2 11±7 
C 66 22±5 71±3 37±1 12±9 
 
TNF c.-308G>A 
G 55 22±4 71±3 37±1 12±9 
A 31 20±5 70±4 38±1 10±7 
 
APOE ɛ2 allele 
Absent 76 21±5 70±4 39±1 11±8 
Present 9 22±6 70±3 32±2 13±12 
CAG length in normal and expanded allele, as well as disease duration is represented as mean ± 
standard deviation; *Age at onset was adjusted for mean CAG length and are represented as mean ± 
standard error;  p<0.05 was considered statistically significant. 
 
